From Care to Cure
Latest Press Releases
Feb 20, 2012
Amsterdam Molecular Therapeutics Receives Request for Further Information from CHMP on Glybera®

Amsterdam, The Netherlands – February 21, 2012 – Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced today that it has received a request to provide additional information to the Committee for Human Medicinal Products...

Feb 20, 2012
Post the announcement of AMT being acquired by uniQure BV, we invite you to an informational meeting on the transaction.

In conjunction with the announcement on Friday  February 17, 2012 of AMT’s Business being acquired by uniQure BV,  we are  pleased to invite you to our company on February 23, 2012 from 11.00 – 13:00  at AMT, 61 Meibergdreef in Amsterdam for an informational meeting on the ...

Feb 17, 2012
Amsterdam Molecular Therapeutics Business to be Acquired by uniQure BV

Extraordinary Shareholder Meeting called to vote on the Transaction

Amsterdam, The Netherlands – February 17, 2012 – Amsterdam Molecular Therapeutics (Euronext: AMT) announced today that its board of directors is recommending a substantial...

Jan 30, 2012
Amsterdam Molecular Therapeutics Announces European Commission Delays Decision on Glybera® Marketing...

Amsterdam, The Netherlands – January 30, 2012 – Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, was informed on Friday January 27, 2012 after business hours that the European Commission’s Standing Committee discussed on Monday January 22,...

Jan 4, 2012
Amsterdam Molecular Therapeutics Receives US Orphan Designation for Hemophilia B Gene Therapy

Amsterdam, The Netherlands – January 4, 2011 – Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to its gene therapy program for the treatment...

Dec 30, 2011
Amsterdam Molecular Therapeutics Announces € 2.5 Million Equity Raise

Dec 15, 2011
Amsterdam Molecular Therapeutics Announces Negative Equity Position

Nov 17, 2011
Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011

Nov 16, 2011
Amsterdam Molecular Therapeutics Receives Orphan Designation in the European Union for Hemophilia B Gene Therapy

Oct 25, 2011
Amsterdam Molecular Therapeutics Provides Operations Update and Strategic Review of Pipeline

Oct 21, 2011
Amsterdam Molecular Therapeutics Receives Opinion on Re-examination of Glybera® Marketing Authorisation

Oct 7, 2011
October 7, 2011 - Company visit AMT

Aug 25, 2011
Amsterdam Molecular Therapeutics Reports Half-Year Results 2011

Jul 8, 2011
Amsterdam Molecular Therapeutics Files Glybera® European Marketing Application for Re-examination

Jul 6, 2011
Amsterdam Molecular Therapeutics Appoints Dr. Carlos R. Camozzi as Chief Medical Officer

Jun 29, 2011
Amsterdam Molecular Therapeutics’ Glybera® Significantly Reduces the Risk of Pancreatitis in LPLD Patients

Jun 24, 2011
Amsterdam Molecular Therapeutics Receives Opinion on Glybera Marketing Authorisation Application

May 26, 2011
AMT's Cooperative Research and Development Agreement With NIH to Boost Production Capacity

May 23, 2011
AMT Research Demonstrates AAV Delivery May Be Key Success Factor for Therapeutic Promise of RNAi

May 20, 2011
AMT Presents Data Supporting Role of Chylomicron Clearance as Marker for Glybera Efficacy

May 19, 2011
AMT Provides Business Update for the First Quarter

May 10, 2011
AMT Provides Status Update on Glybera

Mar 23, 2011
AMT Notice of Annual General Meeting

Mar 7, 2011
AMT receives grant from Dutch parents organization for Duchenne Muscular Dystrophy gene therapy

Feb 16, 2011
Amsterdam Molecular Therapeutics Reports Full Year Results 2010

Feb 8, 2011
AMT to Release Full Year 2010 Results on Wednesday February 16, 2011

Jan 31, 2011
AMT Receives €1.1 Million Funding for Acute Intermittent Porphyria Gene Therapy as Part of EU Consortium Grant

Jan 10, 2011
AMT to Supply cGMP Manufacturing to Consortium Led by Institut Pasteur for Development of Sanfilippo B Gene Therapy Product

Jan 6, 2011
AMT Announces that Steven H. Holtzman Has Resigned as a Member of the Supervisory Board Due to Appointment at Biogen Idec

Archived News Releases

2011

2010

2009

2008

2007

Certain statements in this press release are “forward-looking statements” including those that refer to management’s plans and expectations for future operations, prospects and financial condition. Words such as “strategy,” “expects,” “plans,” “anticipates,” “believes,” “will,” “continues,” “estimates,” “intends,” “projects,” “goals,” “targets” and other words of similar meaning are intended to identify such forward-looking statements. Such statements are based on the current expectations of the management of AMT only. Undue reliance should not be placed on these statements because, by their nature, they are subject to known and unknown risks and can be affected by factors that are beyond the control of AMT. Actual results could differ materially from current expectations due to a number of factors and uncertainties affecting AMT’s business. AMT expressly disclaims any intent or obligation to update any forward-looking statements herein except as required by law.